

## Psoriasis

### ■ Newer Biological Agents

- Alefacept ; Fusion protein of Fc receptor of human IgG1 and LFA3. (IM; when effective long remissions; monitoring of CD4 q wk; slow onset)
- Efalizumab ; Humanized monoclonal antibody to CD11 a; blocks LFA-1/ ICAM interaction. (SC; rapidly effective, but rebound; risk of thrombocytopenia)
- Etanercept ; Fusion protein directed against soluble TNFa(SC; effective for psoriasis & psoriatic arthritis; rapid onset; no monitoring; use +/- MTX)
- Infliximab ; Chimeric monoclonal antibody against TNFa (IV; Fast onset and very effective; must do PPD; infusion reactions.
- Adalimumab ; Fully humanized anti-TNF monoclonal antibody (SC; newest of the biologics, still being studied.

Note TNF drugs avoid or use with caution in presence of CHF, demyelination disorders. Increased risk of opportunistic infections.

[OCR from images: ]